APS Stock Overview
A clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Aptose Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.10 |
| 52 Week High | CA$69.90 |
| 52 Week Low | CA$3.57 |
| Beta | 1.13 |
| 1 Month Change | -27.66% |
| 3 Month Change | -52.11% |
| 1 Year Change | -91.87% |
| 3 Year Change | -99.25% |
| 5 Year Change | -99.87% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation
Mar 26
We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Dec 08We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate
Aug 05We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
Apr 02Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth
Sep 30Shareholder Returns
| APS | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -2.3% | -1.2% | 1.5% |
| 1Y | -91.9% | 13.9% | 10.9% |
Return vs Industry: APS underperformed the Canadian Biotechs industry which returned 13.3% over the past year.
Return vs Market: APS underperformed the Canadian Market which returned 10.8% over the past year.
Price Volatility
| APS volatility | |
|---|---|
| APS Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.3% |
Stable Share Price: APS's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: APS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 36 | William Rice | www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.
Aptose Biosciences Inc. Fundamentals Summary
| APS fundamental statistics | |
|---|---|
| Market cap | CA$11.24m |
| Earnings (TTM) | -CA$51.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs APS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.80m |
| Earnings | -US$35.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -109.5% |
How did APS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 18:41 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aptose Biosciences Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Dylan Dupuis | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |